Introduction {#S0001}
============

The Department of Defense estimates that over 300 000 active duty service members sustained one or more traumatic brain injuries (TBIs) during Operations Iraqi Freedom and Enduring Freedom, with many personnel experiencing multiple TBIs \[[@CIT0001]\]. TBIs significantly increase risk for the onset of neurodegenerative processes and chronic neurological symptoms, especially when sustained multiple times \[[@CIT0002]\] and increase the risk for neurological and psychological symptoms \[[@CIT0003]\]; however, this risk is not universal and is not well understood. Neurodegenerative conditions such as chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD) are linked to TBIs \[[@CIT0004],[@CIT0005]\], suggesting that TBIs involve neurological changes that may exacerbate some common neurodegenerative pathways that contribute to chronic neurological symptoms and deficits.

CTE is a tauopathy characterized by the deposition of hyperphosphorylated tau (p-tau) protein as neurofibrillary tangles, pathological processes that are also likely related to A*β* neuronal accumulations; however, this relationship is not definitive and is influenced greatly by age \[[@CIT0006]\]. Recently, deployment-related TBIs have been linked to high concentrations of total tau in the peripheral blood in a similar cohort of active duty service members with chronic symptoms, suggesting for the first time that these neurodegenerative processes can be detected in individuals with mild-to-moderate TBIs \[[@CIT0007]\]. This finding led the authors to question the role of A*β* in chronic symptoms following TBI in a sample of young active duty service members and to determine if use of a more sensitive detection method, which allows for A*β* measurement in peripheral blood, will provide evidence of A*β* involvement in TBI and chronic symptoms. In search of a minimally-invasive biomarker of TBI, there is interest in using peripheral blood concentrations of proteins to indicate injury severity. If a relationship between TBI and A*β* concentrations is found, it could possibly be used---along with tau---to create a prognostic biomarker for TBI patients.

Although PET studies continue to link tau accumulations to TBIs and chronic neurological symptoms \[[@CIT0008]\], the relationship between TBIs and formation of cerebral A*β* plaques has only been substantiated in subjects over the age of 50 years \[[@CIT0009]\]. In severe TBI, one study found decreased brain extracellular concentration of A*β*, a finding that may indicate TBI-induced suppression of neuronal activity \[[@CIT0010]\]. In peripheral blood samples, only one study has linked A*β* to TBIs, with higher concentrations in the blood during the acute recovery period after severe TBIs and the highest concentrations correlating with mortality risk \[[@CIT0011]\]. A*β*40 and A*β*42 are the two major isoforms of A*β*. They form from cleavage of the amyloid precursor protein and are the two amyloid peptides implicated in toxic plaque formation \[[@CIT0012],[@CIT0013]\]. A*β*42 is considerably more hydrophobic and is, therefore, more likely to aggregate and form plaques than A*β*40 \[[@CIT0012]\]. There is interest in using the ratio of the two amyloid peptides as a biomarker of injury severity. Although the secondary injury pathway is not fully understood, there is evidence the amyloid peptide ratio could be an indicator of amyloid plaque formation or other TBI-related pathology. The plasma ratio of A*β*42/A*β*40 has been shown to correlate with AD pathology \[[@CIT0013]--[@CIT0016]\]. One study showed that an increase in A*β*40/42 ratios was associated with less plaque formation \[[@CIT0015]\]. Another study of patients with Alzheimer's disease correlated cognitive decline with a decrease in A*β*42/40 ratios \[[@CIT0013]\].

Although these studies suggest a relationship between TBIs and A*β* peptides in the brain and periphery, no work has been undertaken to measure concentrations of A*β* in the peripheral blood of chronic TBI patients. This is due in part to the limits of previous technology in measuring A*β* peptides in the peripheral blood of patients with less severe TBIs. The concentrations of CNS proteins leaked to the plasma are in low concentrations that conventional analogue immunoassays are insufficiently sensitive enough to measure. The Simoa technology introduced by Quanterix Inc. (Lexington, MA) uses femtoliter-sized wells capable of trapping individual molecules and using a digital readout of beads to determine if they are bound to the target molecule---A*β* in this case. This ultrasensitive technology allows for detection of A*β* with increased sensitivity---over 1000 times more sensitive than conventional assays.

This exploratory study aims to fill a gap in the literature about chronic A*β*40 and A*β*42 concentrations in TBI patients by utilizing the novel Simoa methodology. It is hypothesized there will be a significant difference in concentrations of A*β*40 and A*β*42 between those who had a TBI (TBI+) and those who did not have a TBI (TBI--). If these differences are found, it may play a role in establishing A*β* as a peripheral biomarker that can help track central neurodegenerative processes related to chronic neurological symptoms following TBI. This line of research is necessary to determine the role of A*β*40 and A*β*42 in chronic neurological symptoms in a younger cohort who have often sustained multiple TBIs during deployment.

Methods {#S0002}
=======

Participants {#S0002-S2001}
------------

This was a prospective observational assessment of 71 active duty personnel who volunteered and consented to be in a larger research study at Madigan Army Medical Center that examined symptoms and biomarkers related to deployment. In the total study, there were a 172 participants who provided clinical information. For this sub-study, participants who provided blood and matched TBI cases to controls in demographics and clinical characteristics were included. This study was approved by the Institutional Review Board at Madigan Army Medical Center in Tacoma, WA. The patients provided voluntary informed consent and completed self-report questionnaires. The Warrior Administered Retrospective Casualty Assessment Tool (WARCAT) was used to determine if participants in this sample had a TBI, as well as the number of TBIs and the severity of the TBI. Controls were subjects who were similar to cases but did not report a TBI determined by the WARCAT. All participants had deployed within 16 months prior to sample collection. Exclusion criteria included the following: (1) history of drug or alcohol abuse in the previous year, (2) current severe medical conditions requiring chronic treatment (e.g. cancer, diabetes, HIV, autoimmune disorders) or a severe psychiatric condition (i.e. schizophrenia, bipolar disorder) and (3) severe neurological disorders (e.g. multiple sclerosis, seizure disorders, history of stroke). This study was approved by the Institutional Review Board (\#145947) and informed consent was obtained from each individual prior to any baseline measurements.

Procedures for determining TBI groups {#S0002-S2002}
-------------------------------------

Fifty-three individuals with a history of TBI (TBI+) were identified by either self-reporting a TBI on the Warrior Administered Retrospective Casualty Assessment Tool (WARCAT) or by having a documented TBI in their medical record. Eighteen participants without a medical history of TBI in their records or a self-reported TBI on the WARCAT were classified as controls (TBI--). The military medical record was used to extract diagnosis of TBI and/or treatment for TBI during deployment. The WARCAT assesses war-related and post-deployment injuries by investigating the mechanism of injury as well as by asking about immediate symptoms or loss of consciousness after injury, indications that a subject sustained a TBI. Controls were matched to TBI cases as much as possible on critical variables that would have influenced biomarkers, including the following: age, gender, ethnicity, time since deployment and military rank.

Collection methods {#S0002-S2003}
------------------

Plasma samples were obtained from non-fasting subjects into EDTA tubes, transported on ice, centrifuged, aliquoted and frozen at --80°C. Subject availability varied such that collection times ranged from 9:00 a.m. to 4:00 p.m. (mean = 11:36 a.m.; SD = 1 hour, 54 minutes). Samples were thawed and analysed in a single batch.

Measures {#S0002-S2004}
--------

A*β*40 and A*β*42 concentrations in plasma samples were analysed using Simoa, a high-definition-1 analyser, which is a paramagnetic bead-based ELISA. The kit includes a monoclonal anti-A*β*40 and 42 capture antibody directed to the N-terminus (Covance 6E10) and a biotinylated detector with a monoclonal anti-A*β*40 and A*β*42 antibody (ADx Neurosciences ADx and Invitrogen H31L21, respectively) directed to the C-terminus (Quanterix, Inc.) \[[@CIT0011]\]. The A*β*40 and A*β*42 assays have a low limit of detection of 0.76 pg ml^--1^ and 0.034 pg ml^--1^, respectively. The reported CV (intra- and inter-plate) values were below 10% for both A*β*40 and A*β*42. Samples with a CV value higher than 10% were excluded from analysis.

Symptoms of PCS were measured using the Neurobehavioural Symptom Inventory (NSI), a self-report measure evaluating 22 symptoms (e.g. balance, nausea and headache). The presence and severity of each symptom is evaluated on a 5-point scale: none, mild, moderate, severe, very severe). A total score is obtained by summation of each symptom score (range = 0--88), where a higher total score indicates higher symptom severity. The NSI has high internal consistency (total alpha = 0.95; sub-scale alpha = 0.88--0.92) and reliability (*r* = 0.88--0.93) \[[@CIT0017]\].

PTSD symptoms were measured using the PTSD Checklist Military Version (PCL-M), which has a score ranging from 0--80. Higher scores indicate higher severity, and a score over 50 indicates a clinical diagnosis of PTSD \[[@CIT0018]\].

Depression symptoms were measured using the Quick Inventory of Depressive Symptomatology (QIDS), which has a score ranging from 0--27. Higher scores indicate high severity and a score over 13 indicates a clinical diagnosis of depression \[[@CIT0019]\].

Statistical analysis {#S0002-S2005}
--------------------

Descriptive statistics for all demographic and clinical variables were calculated using SPSS Statistics (IBM SPSS Inc., Chicago, IL; [Table I](#T0001){ref-type="table"}). Comparisons were made between the two groups using Chi-square for categorical variables, analysis of variance (ANOVA) for continuous variables and analysis of covariance (ANCOVA) when adjusting for covariates. ANOVA models were used to compare A*β*40 and A*β*42 concentrations and the ratio of A*β*42 and A*β*40 in active duty service members who sustained a TBI to controls with no TBI. Lastly, the Spearman rank correlation coefficient was used to determine correlations between A*β*40 and A*β*42 concentrations, the A*β*42/A*β*40 ratio, injury characteristics, and clinical symptoms of PTSD and depression.Table I.Demographics and clinical characteristics for TBI-- and TBI+ groups (*n* = 71). TBI-- (*n* = 18)TBI+ (*n* = 53)SignificanceMean age in years (SD)28.91 (5.49)30.56 (8.78)*F*~1,70~ = 1.38, *p* = 0.41Gender, % (*n*)   Male100.0% (18)98.1% (52)*χ*^2^ = 0.89, *p* = 0.89Race, % (*n*)  *χ*^2^ = 1.19, *p* = 0.66Caucasian83.3% (15)88.7% (47) African American5.2% (1)7.5% (4) Mixed Race5.2% (1)1.8% (1) Hispanic/Latino5.2% (1)1.8% (1) PTSD (PCL-M), Mean (SD)24.33 (10.84)36.21 (13.05)*F*~1,68~ = 7.32, *p* \< 0.01*n* (% PTSD Dx)5 (27.78)13 (24.52)*χ*^2^ = 0.79, *p* = 0.86Depression (QIDS), Mean (SD)7.0012.85 (4.08)*F*~1,67~ = 6.52, *p* \< 0.01*n* (% Depression Dx)5 (27.78)14 (26.41)*χ*^2^ = 0.74, *p* = 0.79PCS (NSI), Mean (SD)26.33 (13.55)38.39 (14.20)*F*~1,58~ = 6.84, *p* \< 0.01[^1]

Results {#S0003}
=======

This sample consisted of 71 active duty service members who were primarily male and who had deployed within the previous 16 months to combat stations ([Table I](#T0001){ref-type="table"}). The mean time since latest deployment was 9.7 months (SD = 5.0) and the mean time since the most severe deployment-related TBI was 20.6 months (SD = 12.3). The TBI+ (*n* = 53) and TBI-- (*n* = 18) groups did not differ significantly in age or gender. The TBI+ group had significantly more symptoms of PTSD, depression and PCS. In the TBI+ group, the mean number of TBIs was 3.89 (SD = 1.93) and \~ 56.6% had a loss of consciousness ranging from less than a minute to 20 minutes, with 9.4% having a loss consciousness of more than 20 minutes in duration ([Table 2](#T0002){ref-type="table"}). Approximately 38.43% of the TBI+ group had a medical diagnosis of TBI or had documentation of receiving care for a TBI during deployment. These ICD codes included the following: 85.40 or 959.01.Table II.TBI characteristics according to the WARCAT. *n*%*Severity of TBI*  Dazed/confused/seeing stars2241.51%Not remembering injury2037.73%LOC \< 1 minute2649.05%LOC 1--20 minutes1120.75%LOC \> 20 minutes59.43%*TBI symptoms after injury*  Headache3362.64%Memory problems2445.28%Balance problems2037.73%Irritability2649.05%Sleeping problems3158.49%

Concentrations of A*β*40 were significantly higher in the TBI+ group than the TBI-- group (*F* ~1,68~ = 6.948, *p* = 0.009; [Figure 1](#F0001){ref-type="fig"}(*a*)). Concentrations of A*β*42 tended to be higher in the TBI+ group than the TBI-- group (*F* ~1,64~ = 2.979, *p* = 0.089; [Figure 1](#F0001){ref-type="fig"}(*b*)) in active duty service members The ratio of A*β*42/A*β*40 was also significantly different between the groups (*F* ~1,62~ = 5.671, *p* = 0.020), with the ratio being significantly lower in the TBI+ group ([Figure 2](#F0002){ref-type="fig"}). In an ANCOVA model controlling for PTSD and depression, A*β*40 (*F* ~1,68~ = 3.32, *p* = 0.025) and the ratio of A*β*42/A*β*40 (*F* ~1,62~ = 5.01, *p* = 0.03) remained significantly different between the TBI+ and TBI-- groups. Symptomatology of PTSD and depression was not related to concentrations of A*β*40 or A*β*42 in a correlation analysis of the ratio of A*β*42/A*β*40.Figure 1.(*a*) Concentrations of A*β*40 were significantly different (*F* ~1,68~ = 6.948, *p* = 0.009), with higher concentrations in the TBI+ group compared to TBI-- controls. (*b*) Concentrations of A*β*42 tended to be different (*F* ~1,64~ = 2.979, *p* = 0.089), with a tendency to have higher concentrations in the TBI+ group compared to TBI-- controls. Figure 2.The ratio of A*β*42/A*β*40 was also significantly different between the groups (*F* ~1,62~ = 5.671, *p* = 0.020), with the ratio being significantly lower in the TBI+ group compared to TBI-- controls.

Discussion {#S0004}
==========

This study reports for the first time that A*β*40 is elevated and the A*β*42/A*β*40 ratio is lower in the blood of young males with a history of deployment-related TBIs compared to those without a TBI. This finding provides insight into the mechanisms related to the onset of chronic neurological symptoms, which may lead to neurodegenerative processes later in life and the onset of CTE- and AD-related deficits \[[@CIT0003],[@CIT0020]\]. Neurodegenerative processes, such as AD and CTE, include senile plaques and intracellular neurofibrillary tangles formed by hyper-phosphorylated tau in older individuals with A*β* accumulation \[[@CIT0009]\]. Previously, it has been shown that, in active duty service members, tau is also chronically elevated in individuals who have sustained a TBI compared to controls \[[@CIT0007]\]. The current study adds a novel investigation concerning peripheral A*β* concentrations in chronic TBI patients from a similar military cohort. This report now shows that A*β* also remains chronically elevated for months to years after sustaining a TBI, suggesting that the neuropathology may be related to that of AD and CTE.

Although one limitation to this study is that it is reliant on peripheral samples that cannot be generalized to central samples and processes, other studies suggest that these peripheral elevations result from TBI-induced axonal injuries \[[@CIT0021],[@CIT0022]\]. Elevated A*β* concentrations suggest that there is an on-going neural injury, potentially leading to neurodegeneration, and that blood--brain barrier disruption may persist for long periods following TBI. While it is highly controversial whether amyloid plaques are toxic, there is ample experimental evidence to suggest that oligomeric forms of A*β* may be synaptotoxic and neurotoxic, promoting disruptions in cellular membrane and mitochondrial function and activating microglia to induce neuroinflammatory processes, with A*β*42 being more toxic than A*β*40 \[[@CIT0023]--[@CIT0030]\]. The plasma ratio of A*β*42/A*β*40 has been shown to be consistently associated with AD pathology \[[@CIT0013]--[@CIT0016]\] and plaque formation \[[@CIT0015]\]. Moreover, a study with patients with Alzheimer's disease correlated cognitive decline with a decrease in A*β*42/40 ratios \[[@CIT0013]\]. Similarly, in this study, the ratio of A*β*42/A*β*40 was significantly lower in the TBI+ group. Although this finding suggests the ratio of A*β*42/40 could be a useful biomarker of neurodegeneration, there are limitations to the Simoa technology used in this study. It is possible that, because A*β*42 is more hydrophobic and prone to aggregation, Simoa's ability to differentiate between oligomers and monomers is impeded, thereby resulting in an under-estimation of the peripheral concentrations of A*β*42 and affecting the ratio \[[@CIT0031]\]. This will require further study to differentiate the meaning of the ratio in chronic TBI and replication of this study using digital immunoassay technology advances.

The findings are also consistent with previous findings in TBI and CTE research \[[@CIT0032]--[@CIT0036]\]. A recent study using amyloid PET scans showed that patients who sustained a mild TBI, an average of 6 years prior to the study, had increased concentrations of amyloid, and these accumulations were associated with cognitive impairments in a sample of older subjects \[[@CIT0037]\]. In this sample of younger subjects, it was seen that individuals with TBIs, irrelevant of symptoms, have a higher concentration of A*β*40. In studies of CTE, it is reported that, in the earlier stages, the predominant symptoms are neurobehavioural and then progress to cognitive deficits \[[@CIT0038]\] and that cognitive symptoms only occur in older individuals with CTE, suggesting that age may be a contributor to A*β* accumulation and cognitive symptoms \[[@CIT0037]\]. Interestingly, epidemiological studies suggest that a TBI stimulates the accumulation of central A*β* and considerably shortens the time of onset of AD from 18 to 10 years \[[@CIT0020]\]. Indeed, a single TBI may result in neurofibrillary tangle and senile plaque formation that can promote the development of neurodegenerative processes and neurological disorders \[[@CIT0039]\]. Taken together with previous studies, the findings suggest that active duty service members exposed to TBI during combat may be at higher risk for developing AD or CTE. This diagnosis could present a window of opportunity for studying mechanisms of the neurodegenerative process and help slow the progression. Thus, in this younger cohort, it is likely that the A*β*-related neurodegenerative processes have not yet resulted in substantial cognitive-related deficits and it may be that these peripheral elevations are early indicators of neurodegeneration. This study suggests that these younger cohorts are followed over time to determine the relationship between AB and cognitive symptoms.

Although these findings suggest future implications, some limitations to this study are the sample size and lack of follow-up data. Additional studies with larger sample sizes and more long-term follow-up are necessary to determine the role of A*β* in TBI and chronic symptoms. In addition, the method to measure A*β* in a peripheral sample provides an opportunity to examine possible links in patients with non-severe traumatic brain injuries; however, these findings do not provide the necessary information to understand the role of neuronal A*β* accumulation in the formation of neurofibrillary tangles and risk for CTE without corroborating evidence in the form of imaging results or cerebrospinal fluid. Another limitation is the variable time of sample collection following head injury. Additional efforts should be made for prospective studies that acquire samples immediately after TBI and follow them longitudinally. Long-term prospective studies would help elucidate the temporal changes in post-TBI amyloid accumulations, which in turn would provide a clearer understanding of injury-catalysed biochemical cascades and support the use of these proteomic markers as prognostic tools.
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